Reindeer Antler BMP-4 with Heparin Binding Site
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and producing bone morphogenetic proteins (BMPs), particularly BMP-4, are challenging due to high homology and similarity with other BMPs, making separation, purification, and identification difficult, and existing recombinant production methods do not fully utilize the unique properties of BMPs from species like reindeer antlers.
Innovation Solution
The development of recombinant BMP-4 from reindeer antlers with a heparin binding site, which improves expression and biological activity, and the use of specific amino acid sequences such as Pro6 and Pro21, enhancing bone and cartilage formation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional isolation and purification methods are used for BMPs, then BMPs can be obtained from bone matrix, but the process is very time consuming and expensive due to high homology and difficulty in separation
Solution Approach 1:
The patent replaces traditional mechanical/chemical separation methods with molecular biological tools (recombinant DNA technology) to produce BMPs. By cloning the BMP-4 gene into expression vectors and using recombinant protein expression systems, the invention eliminates the need for time-consuming separation and purification of BMPs from bone matrix, directly producing pure recombinant BMP-4 protein.
2Ease of manufacture
If recombinant protein techniques are used to produce BMPs, then production can be achieved, but existing methods do not fully utilize the unique properties of BMPs from species like reindeer antlers
Solution Approach 1:
The patent applies local quality by incorporating specific amino acid sequences (Pro6 and Pro21) that are unique to reindeer antler BMP-4 into the recombinant protein structure. These localized structural features enhance the osteoinductive activity of the recombinant BMP-4, making it more effective than human BMP-4 while maintaining the benefits of recombinant production.
3Manufacturing precision
If BMPs with high homology are separated and purified, then all BMP variants can be identified, but the process is very expensive and time consuming
Solution Approach 1:
The patent extracts only the essential BMP-4 gene sequence from the complex bone matrix environment using molecular biological techniques. By isolating and cloning the specific gene of interest rather than attempting to separate and purify multiple BMP variants from tissue, the invention simplifies the process while maintaining high precision in obtaining the desired BMP-4 protein.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant BMP-4 from reindeer antlers demonstrates significantly improved bone induction potency compared to human BMP-4, with enhanced expression and biological activity, making it a more effective osteoinductive agent for clinical applications.
Implementation Method 1
The development of recombinant BMP-4 from reindeer antlers with a heparin binding site, which improves expression and biological activity
Implementation Method 2
Between these cysteines there are three disulfide bonds within mature BMP monomers and one disulfide bond which combines two monomers into a biologically active BMP dimer
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 4 (BMP-4) and nucleotide molecules encoding said proteins and host cells expressing said proteins. The present invention relates also to the use of said BMP-4 for treating disorders related to bone and cartilage formation. The present invention further relates to osteogenic devices and pharmaceutical compositions containing said proteins.